{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:23:29Z","timestamp":1770884609350,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Neuroleptic malignant syndrome (NMS) is a rare, life-threatening complication of neuroleptic (antipsychotic) medications. Paliperidone is an atypical antipsychotic used in the treatment of schizophrenia. While current evidence suggests that atypical oral antipsychotics have a lower incidence of NMS compared to typical oral antipsychotics, there is limited information available on the incidence and management of NMS associated with long-acting injectable (LAI) antipsychotics. More case studies are needed to fully understand the true incidence of NMS associated with LAI atypical antipsychotics. This report aims to present our experience with a patient with schizophrenia who developed NMS as a result of taking LAI paliperidone, an atypical antipsychotic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 63-year-old male diagnosed with schizophrenia was brought to the emergency room with complaints of high fever, muscle contraction, tremors, urinary and fecal incontinence, and a change of consciousness, which started 2 days after the first LAI paliperidone injection. During the psychiatric examination, the patient exhibited tremors, a high fever of 39.5\u00b0C, and muscle rigidity. He was confused and had impaired orientation. The patient\u2019s creatine kinase, white blood cell count, aspartate aminotransferase, and alanine aminotransferase levels were measured at 1895\u2005U\/L, 13750\/mm<jats:sup>3<\/jats:sup>, 55\u2005IU\/L, and 45\u2005IU\/L, respectively. The electrocardiogram showed sinus tachycardia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient\u2019s psychiatric examination, vital signs, and laboratory results were consistent with NMS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received treatment with bromocriptine and amisulpride for 13 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>With this treatment, the patient\u2019s delirium improved and the patient became stable. The levels of creatine kinase, white blood cell count, aspartate aminotransferase, and alanine aminotransferase decreased to normal values. The patient was discharged from the hospital after 14 days of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Although NMS is not very common in patients using antipsychotics, it is important because it is an emergency condition that can result in death if not treated appropriately. Clinicians should consider NMS in patients taking atypical antipsychotics such as paliperidone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041171","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:42:44Z","timestamp":1743208964000},"page":"e41171","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Paliperidone-induced neuroleptic malignant syndrome: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-9729","authenticated-orcid":false,"given":"Gonca Ayse","family":"Unal","sequence":"first","affiliation":[{"name":"Clinic of Psychiatry, Mersin Sehir Egitim ve Arastirma Hastanesi, Toroslar, Mersin, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/NDT.S118438","article-title":"Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.","volume":"13","author":"Oruch","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"suppl 1","key":"R2-20250328","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.918","article-title":"Neurological complications of psychiatric drugs: clinical features and management.","volume":"23","author":"Haddad","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome.","volume":"164","author":"Strawn","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200923060-00003","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.","volume":"23","author":"Trollor","year":"2009","journal-title":"CNS Drugs"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"699748","DOI":"10.3389\/fpsyt.2021.699748","article-title":"Paliperidone 3-month injection for treatment of schizophrenia: a narrative review.","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front Psychiatry"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/jnp.2007.19.4.477","article-title":"Possible neuroleptic malignant syndrome associated with paliperidone.","volume":"19","author":"Duggal","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0000000000001019","article-title":"Low incidence of neuroleptic malignant syndrome associated with paliperidone palmitate long-acting injectable: a database report and case study.","volume":"39","author":"Kane","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0b013e3181c9c7ef","article-title":"Possible neuroleptic malignant syndrome during paliperidone administration: a case report.","volume":"30","author":"Mantas","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.pnpbp.2010.12.006","article-title":"Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.","volume":"35","author":"Han","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1176\/jnp.23.4.jnpe16","article-title":"Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.","volume":"23","author":"Teng","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1176\/jnp.23.1.jnpe14","article-title":"Paliperidone-induced neuroleptic malignant syndrome.","volume":"23","author":"Nayak","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1176\/appi.neuropsych.11070156","article-title":"Possible paliperidone-induced neuroleptic malignant syndrome: a case report.","volume":"24","author":"\u00d6zdemir","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/JCP.0000000000000507","article-title":"Atypical neuroleptic malignant syndrome associated with paliperidone long-acting injection: a case report.","volume":"36","author":"Langley-DeGroot","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"R15-20250328","first-page":"2587963","article-title":"Paliperidone inducing concomitantly syndrome of inappropriate antidiuretic hormone, neuroleptic malignant syndrome, and rhabdomyolysis.","volume":"2016","author":"Kaur","year":"2016","journal-title":"Case Rep Crit Care"},{"key":"R16-20250328","first-page":"5584104","article-title":"Neuroleptic malignant syndrome (NMS) on clozapine with a potential atypical interaction with paliperidone.","volume":"2021","author":"Agarwal","year":"2021","journal-title":"Case Rep Psychiatry"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"37530","DOI":"10.52965\/001c.37530","article-title":"Silent neuroleptic malignant syndrome: a case report of atypical antipsychotic induced elevation of creatinine kinase and altered mental status.","volume":"10","author":"Edinoff","year":"2022","journal-title":"Health Psychol Res"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/1060028016657553","article-title":"Neuroleptic malignant syndrome.","volume":"50","author":"Pileggi","year":"2016","journal-title":"Ann Pharmacother"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajp.2017.05.004","article-title":"Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management.","volume":"29","author":"Velamoor","year":"2017","journal-title":"Asian J Psychiatr"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"17r","DOI":"10.4088\/PCC.17r02185","article-title":"Neuroleptic malignant syndrome: diagnosis and management.","volume":"20","author":"Ware","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/acps.13359","article-title":"A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome.","volume":"144","author":"Guinart","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"R22-20250328","first-page":"576","article-title":"Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report.","volume":"33","author":"Tsai","year":"2010","journal-title":"Chang Gung Med J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:50:48Z","timestamp":1743364248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041171","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}